Highlights first quarter 2026:
o Q1 revenues reached USD 57.3 million, an increase of 13% year-over-year (YoY),
with adjusted EBITDA of USD 12.5 million, up 34% from the prior year.
o Human Health Ingredients delivered USD 31.8 million in revenue, up 22% YoY.
Krill oil revenues reached an all-time-high of USD 29.3 million, up 26% YoY.
Adjusted EBITDA increased 27% to USD 14.9 million.
o Consumer Health Products generated USD 28.1 million in revenue, down 2% YoY.
Adjusted EBITDA of USD 1.8 million, with margin up YoY on lower SG&A. From Q1
2026, the segment includes both Lang and Epion/Kori
o Refinanced NOK 1,600 million bond with a new USD 175 million term loan
o Emerging Business no longer reported as a separate segment
"The first quarter marks an all-time-high for Superba krill oil sales,
reflecting strong underlying demand across our customer base. Krill oil revenues
grew 26% year-over-year, supported by both higher volumes and improved price
mix. We have now delivered three consecutive years of year-over-year growth in
quarterly krill oil revenues", said Matts Johansen, CEO of Aker BioMarine.
Segment performance
Human Health Ingredients grew revenues by 22% year-over-year, with krill oil
revenues up 26% to USD 29.3 million - an all-time-high quarter for Superba.
Growth was driven mainly by higher volumes, with additional support from an
improved price mix reflecting a higher capsule share. Gross margin came in
slightly below last year due to product mix, while EBITDA margin improved as
SG&A growth remained modest.
Consumer Health Products reported revenues of USD 28.1 million, down 2%
year-over-year. From the first quarter of 2026, the segment includes both Lang
and Epion/Kori, with internal sales and profit eliminated. Lang grew modestly
across most categories, while Epion is in an ongoing marketing repositioning
that is weighing on short-term revenues but is expected to be positive over
time. Gross margin was on par with last year, while EBITDA margin improved on
lower SG&A.
Outlook
The Human Health Ingredients segment sees continued year-over-year growth,
supported by good underlying demand across multiple markets. In Consumer Health
Products, revenues are expected to return to modest growth. The Understory sales
process is still ongoing with advanced discussions with one interested party.
Following recent interest in the Human Health Ingredient business unit, the
Company has engaged Jefferies and Houlihan Lokey as investment banks to support
the Company in exploring alternatives and work towards a transaction in 2026.
Attached is the quarterly presentation and report for Q1. Group reported
financial figures can be downloaded in an excel from the company's investor
page: Investor - Analyst information
At 08:30 CET today, the management hosts a webcast. The webcasted presentation
will be in English. To join, please use the link that is available at
www.akerbiomarine.com/investor.
A replay of the presentation will be made available soon after the presentation
at the same web address.
For further information, please contact
Christopher Robin Vinter, SVP Finance
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.
About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.